Can you imagine a world where you fear your every next step? What if an everyday fall, trip, or slip could mean losing ...

I have the rare condition fibroidodysplasia ossificans progressiva, which causes bone to form into muscles, tendons, ligaments and other connective tissues, progressively restricting movement.

Perfectly sparkling smiles dominate our social media feeds every day, so it’s only natural that many Brits are looking for ways to brighten their gnashers to achieve celebrity-white teeth ...

– Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 ...

Ipsen has suffered a setback in its marathon effort to bring palovarotene to market for ultra rare disease fibrodysplasia ossificans progressiva (FOP), after EU advisors recommended against approval.

– Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $709 ...

Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder.

Three suspects attacked Uber driver Muhammad Jawaid on March 21, knocking out a dozen of his teeth, according to Chicago police. They stole his wallet and phone and tried to steal his car.

– Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $709 million in ...